North Texas Endocrine Center | Dallas, TX

Research site

(Unclaimed)

Location

9301 N. Central Expressway Tower 2, Suite 570, Dallas, Texas, United States of America

Site insights

Top conditions

Top treatments

Tirzepatide

LY3298176

Sugar

Sitagliptin

Vildagliptin

Insulin icodec

Insulin aspart

Metformin

INV-202

Pemafibrate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 28 total trials

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 differen...

Active, not recruiting

Obesity

Drug: Placebo

Drug: Tirzepatide

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Active, not recruiting

Type 2 Diabetes

Drug: Semaglutide

Drug: Cagrilintide

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (REIMAGINE 2)

The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two...

Active, not recruiting

Type 2 Diabetes Mellitus

Drug: Cagrilintide

Drug: Semaglutide

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight (REDEFINE 2)

This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participan...

Active, not recruiting

Overweight

Type 2 Diabetes Mellitus

Drug: Placebo semaglutide

Drug: Placebo cagrilintide

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine (m...

Active, not recruiting

Type 2 Diabetes

Drug: IcoSema

Drug: Insulin glargine

A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction.

Invitation-only

Overweight

Obesity

Drug: Placebo

Drug: Orforglipron

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting

Type 2 Diabetes Mellitus

Drug: Tirzepatide

Drug: Dulaglutide

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo